Treatment with Acceleron Pharma’s sotatercept appears to be effective and generally well tolerated in people with pulmonary arterial hypertension (PAH), according to new data from the ongoing PULSAR and SPECTRA Phase 2 clinical trials. These data will be presented at the American Thoracic Society (ATS) 2021 International…
VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s…
Pulmonary hypertension (PH) occurs in 60% of children with the heart defect known as patent ductus arteriosus, with girls being more likely to develop PH than boys, a study found. A child with patent ductus arteriosus has an opening, or duct, between two major blood vessels leading from the…
Get regular updates to your inbox.